432 related articles for article (PubMed ID: 37328635)
41. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
Pillarisetti K; Edavettal S; Mendonça M; Li Y; Tornetta M; Babich A; Majewski N; Husovsky M; Reeves D; Walsh E; Chin D; Luistro L; Joseph J; Chu G; Packman K; Shetty S; Elsayed Y; Attar R; Gaudet F
Blood; 2020 Apr; 135(15):1232-1243. PubMed ID: 32040549
[TBL] [Abstract][Full Text] [Related]
42. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
Lee H; Neri P; Bahlis NJ
Blood; 2024 Mar; 143(13):1211-1217. PubMed ID: 38194680
[TBL] [Abstract][Full Text] [Related]
43. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
44. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
Mikkilineni L; Sidana S
J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
[TBL] [Abstract][Full Text] [Related]
45. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
[TBL] [Abstract][Full Text] [Related]
46. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
Laheij AMGA; van de Donk NWCJ
Support Care Cancer; 2023 Dec; 32(1):20. PubMed ID: 38092979
[TBL] [Abstract][Full Text] [Related]
47. Antibodies and bispecifics for multiple myeloma: effective effector therapy.
Cipkar C; Chen C; Trudel S
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):163-172. PubMed ID: 36485135
[TBL] [Abstract][Full Text] [Related]
48. [Development of novel bispecific antibody therapy for multiple myeloma].
Konishi T; Ochi T; Takenaka K
Rinsho Ketsueki; 2024; 65(5):428-438. PubMed ID: 38825523
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic progress in relapsed/refractory multiple myeloma.
Chen Q; Zhang M; Zheng S; Tong Y; Tan Y
Ann Hematol; 2024 Jun; 103(6):1833-1841. PubMed ID: 38609727
[TBL] [Abstract][Full Text] [Related]
50. Teclistamab: Mechanism of action, clinical, and translational science.
Guo Y; Quijano Cardé NA; Kang L; Verona R; Banerjee A; Kobos R; Chastain K; Uhlar C; Pillarisetti K; Doyle M; Smit J; Haddish-Berhane N; Ouellet D
Clin Transl Sci; 2024 Jan; 17(1):e13717. PubMed ID: 38266057
[TBL] [Abstract][Full Text] [Related]
51. Targeting BCMA in Multiple Myeloma.
Tan CR; Shah UA
Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
[TBL] [Abstract][Full Text] [Related]
52. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
[TBL] [Abstract][Full Text] [Related]
53. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
[TBL] [Abstract][Full Text] [Related]
54. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
55. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
[TBL] [Abstract][Full Text] [Related]
56. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
Caraccio C; Krishna S; Phillips DJ; Schürch CM
Front Immunol; 2020; 11():501. PubMed ID: 32391000
[TBL] [Abstract][Full Text] [Related]
57. [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].
Ranchon F; Chatelut É; Lambert J; Sesques P; Thibault C; Madelaine I; Rioufol C; Diéras V; Cazin JL
Bull Cancer; 2023 Dec; 110(12):1343-1351. PubMed ID: 37827964
[TBL] [Abstract][Full Text] [Related]
58. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
De Luca F; Allegra A; Di Chio C; Previti S; Zappalà M; Ettari R
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
[TBL] [Abstract][Full Text] [Related]
59. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
Xiong M; Liu R; Lei X; Fan D; Lin F; Hao W; Yuan X; Yang Y; Zhang X; Ye Z; Lu Y; Zhang Y; Wang J; Xiong D
J Immunother; 2022 Feb-Mar 01; 45(2):78-88. PubMed ID: 34711791
[TBL] [Abstract][Full Text] [Related]
60. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
Zhang M; Wei G; Zhou L; Zhou J; Chen S; Zhang W; Wang D; Luo X; Cui J; Huang S; Fu S; Zhou X; Tang Y; Ding X; Kuang J; He XP; Hu Y; Huang H
Lancet Haematol; 2023 Feb; 10(2):e107-e116. PubMed ID: 36725117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
